Noxxon Pharma

company

About

Noxxon Pharma develops biostable aptamers and substances based on mirror image nucleic acids.

  • 51 - 100

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
€1M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 1998
Number Of Employee
51 - 100
Operating Status
Active

NOXXON Pharma AG, a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€2.20M
Noxxon Pharma has raised a total of €2.20M in funding over 2 rounds. Their latest funding was raised on Mar 3, 2021 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 3, 2021 Post-IPO Equity €1.20M 1 Detail
May 2, 2017 Post-IPO Debt €1M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Noxxon Pharma is funded by 1 investors. Kreos Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Kreos Capital Post-IPO Equity